BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang QA, Hamajima Y, Zhang Q, Lin J. Identification of Id1 in acquired middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg 2008;134:306-10. [PMID: 18347258 DOI: 10.1001/archotol.134.3.306] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Li JD, Hermansson A, Ryan AF, Bakaletz LO, Brown SD, Cheeseman MT, Juhn SK, Jung TT, Lim DJ, Lim JH, Lin J, Moon SK, Post JC. Panel 4: Recent advances in otitis media in molecular biology, biochemistry, genetics, and animal models. Otolaryngol Head Neck Surg 2013;148:E52-63. [PMID: 23536532 DOI: 10.1177/0194599813479772] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
2 Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X, Xie D. Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium. Eur Arch Otorhinolaryngol 2014;271:265-73. [DOI: 10.1007/s00405-013-2403-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
3 Miyake S, Miwa T, Yoneda G, Kanemaru A, Saito H, Minoda R, Orita Y, Saito H, Jono H. Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma. PLoS One 2020;15:e0240216. [PMID: 33031450 DOI: 10.1371/journal.pone.0240216] [Reference Citation Analysis]
4 Lin J, Guan Z, Wang C, Feng L, Zheng Y, Caicedo E, Bearth E, Peng JR, Gaffney P, Ondrey FG. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res 2010;16:77-87. [PMID: 20028744 DOI: 10.1158/1078-0432.CCR-08-2362] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
5 Byun JY, Yune TY, Lee JY, Yeo SG, Park MS. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium. Mediators Inflamm 2010;2010:796315. [PMID: 20414373 DOI: 10.1155/2010/796315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
6 Xie S, Wang X, Ren J, Liu W. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. Eur Arch Otorhinolaryngol 2017;274:2071-8. [DOI: 10.1007/s00405-016-4422-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
7 Jung TTK, Alper CM, Hellstrom SO, Hunter LL, Casselbrant ML, Groth A, Kemaloglu YK, Kim SG, Lim D, Nittrouer S, Park KH, Sabo D, Spratley J. Panel 8: Complications and Sequelae. Otolaryngol Head Neck Surg 2013;148:E122-43. [DOI: 10.1177/0194599812467425] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
8 Preciado DA. Biology of cholesteatoma: special considerations in pediatric patients. Int J Pediatr Otorhinolaryngol 2012;76:319-21. [PMID: 22264818 DOI: 10.1016/j.ijporl.2011.12.014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
9 Hamajima Y, Komori M, Preciado DA, Choo DI, Moribe K, Murakami S, Ondrey FG, Lin J. The role of inhibitor of DNA-binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media. Cell Prolif 2010;43:457-63. [PMID: 20887552 DOI: 10.1111/j.1365-2184.2010.00695.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
10 Xie S, Xiang Y, Wang X, Ren H, Yin T, Ren J, Liu W. Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways: Proliferation Pathways in Cholesteatoma. The Laryngoscope 2016;126:1923-30. [DOI: 10.1002/lary.25834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
11 Araz Server E, Kalaycık Ertugay Ç, Baykal Koca S, Longur ES, Yiğit Ö, Demirhan H, Çakır Y. Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma. J Int Adv Otol 2019;15:38-42. [PMID: 30541725 DOI: 10.5152/iao.2018.4976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]